熱門資訊> 正文

哈罗公学子公司ImprimisRx任命新首席执行官

2025-10-06 19:44

Harrow (NASDAQ:HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx; Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx.
Mr. Mullery is a senior executive with over 20 years of leadership experience in the healthcare and pharmaceutical industries.

More on Harrow Health

Harrow, Inc. (HROW) Analyst/Investor Day Transcript
Harrow: Buy A Blend Of Value And Growth
Harrow: A Classical GARP Stock
Harrow to buy Melt Pharmaceuticals
Harrow launches $250M debt offering

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。